Table 4.
Prospective and Registry-based cohort studies reporting progression risk in LGD, since 2000
| AUTHOR(S) | YEAR | SETTING | STUDY DESIGN |
BE PATIENTS FOLLOWED |
MALE | INCIDENCE OF EAC, % PER YEAR, IN NDBE |
INCIDENCE OF EAC OR HGD, % PER YEAR, IN NDBE |
INCIDENCE OF EAC, % PER YEAR, IN LGD |
INCIDENCE OF EAC OR HGD, % PER YEAR, IN LGD |
|---|---|---|---|---|---|---|---|---|---|
| THOTA ET AL141 | 2014 | U.S. | Prospective Cohort |
299 | 79.0 | NR | NR | 0.80% | 3.10% |
| PICARDO ET AL132 | 2014 | U.K. | Prospective Cohort |
1093 | 67.1 | 0.13% | 0.72% | 1.98% | 6.49% |
| DUITS ET AL140 | 2014 | Netherlands | Retrospective Cohort |
293 | 76.0 | NR | 0.60% | NR | 9.10% |
| RUGGE ET AL131 | 2012 | Italy | Prospective Cohort |
841 | 77.0 | NR | 0.53% | NR | 3.17% |
| HVID-JENSEN ET AL10 | 2011 | Netherlands | Prospective Cohort |
11028 | 66.8 | 0.09% | 0.25% | 0.55% | 1.67% |
| BHAT ET AL11 | 2011 | U.K. | Retrospective Cohort |
8522 | 57.9 | 0.10% | 0.15% | 0.92% | 1.31% |
| WANI ET AL107 | 2011 | U.S. | Prospective Cohort |
1755 | 85.0 | NR | NR | 0.44% | 1.83% |
| SCHOUTEN ET AL139 | 2011 | Netherlands | Retrospective Cohort |
605 | 54.0 | 0.30% | NR | 0.41% | NR |
| DE HOED ET AL130 | 2011 | Netherlands | Prospective Cohort |
133 | 54.9 | NR | 0.35% | NR | 1.62% |
| JUNG ET AL138 | 2011 | U.S. | Retrospective Cohort |
355 | 72.0 | 0.25$ | 0.66% | 0.23% | 0.71% |
| DE JONGE ET AL122 | 2010 | Netherlands | Retrospective Cohort |
42207 | 62.5 | 0.39% | 0.51% | 0.77% | 1.06% |
| CURVERS ET AL137 | 2010 | Netherlands | Retrospective Cohort |
1198 | 67.0 | NR | 0.49% | 0.34% | 13.40% |
| WONG ET AL136 | 2010 | U.S. | Retrospective Cohort |
248 | NR | 0.51% | 0.61% | 1.51% | 1.51% |
| GATENBY ET AL121 | 2009 | U.K. | Retrospective Cohort |
146 | NR | NR | NR | 2.70% | 4.60% |
| ALCEDO ET AL135 | 2009 | Spain | Retrospective Cohort |
386 | 79.0 | 0.52% | 0.95% | 0.00% | 0.00% |
| SWIZER-TAYLOR ET AL129 | 2008 | U.K. | Retrospective Cohort |
212 | 69.0 | 0.68% | 0.85% | 0.75% | 3.16% |
| LIM ET AL128 | 2007 | U.K. | Retrospective Cohort |
357 | 57.7 | NR | 0.62% | NR | 3.30% |
| VIETH EL AL134 | 2006 | Germany | Retrospective Cohort |
748 | 67.8 | 0.23% | 0.23% | 4.67% | 4.67% |
| DULAI ET AL127 | 2005 | U.S. | Retrospective Cohort |
575 | 99.0 | 0.09% | 0.36% | 36.00% | 1.28% |
| CONIO ET AL126 | 2003 | Italy | Prospective Cohort |
166 | 81.3 | 0.36% | 0.61% | 2.27% | 3.44% |
| SCHNELL ET AL133 | 2001 | U.S. | Retrospective Cohort |
1099 | NR | NR | NR | 0.19% | NR |
| WESTON ET AL114 | 2001 | U.S. | Prospective Cohort |
48 | 100.0 | NR | NR | 0.61% | 2.43% |
| REID ET AL108 | 2000 | U.S. | Prospective Cohort |
327 | NR | 1.05% | NR | 1.50% | NR |
| SKACEL ET AL113 | 2000 | U.S. | Retrospective Cohort |
25 | 84.0 | NR | NR | 0.15% | 0.52% |